RxDoctor Payments Data

Ralph Irvin, MD

Pain Medicine · Mobile, ALNPI 1760482111

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 33.3% of the total. Reporting peaked in 2021 at $569 and has fallen 86.2% since, to $78 in 2024.

$2,412in general payments, 2019–2025

Across 176 payments — averaging $13.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$803
  • Forte Bio-pharma LLC$305
  • Collegium Pharmaceutical, Inc.$217
  • Medtronic$214
  • Nevro Corp.$189
  • Abbott$136
  • plus $548 from 14 others

What the payments were for

  • Food & beverage$2,412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,412 in reported general payments places this provider in the 60th percentile of 77 pain medicine providers in Alabama.

See all pain medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$39,376
Medicare patients
327
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen308$35,546
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen474$14,529
MovantikNaloxegol Oxalate21$9,371
Xtampza ErOxycodone Myristate13$9,091
LinzessLinaclotide12$7,532
Gabapentin416$4,312
Diclofenac Sodium55$2,307
Pregabalin111$1,550
Cyclobenzaprine Hcl208$1,477
Tizanidine Hcl170$1,417
Oxycodone Hcl81$1,235
Morphine Sulfate ErMorphine Sulfate33$923
Celecoxib56$876
Baclofen66$637
Methadone Hcl25$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$44$9,37121 claims
Collegium Pharmaceutical, Inc.Xtampza Er$217$9,09113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 77 pain medicine providers in Alabama.

Other pain medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →